Halaven 2ml Solution for injection
PDF Leaflet Revision Date: 6 March 2025
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of advanced breast cancer and unresectable liposarcoma after prior therapy.
Dosage (summary)
1.23 mg/mu00b2 IV on Days 1 and 8 of a 21-day cycle.
Special Populations
- Hepatic impairment
- Renal impairment
- Elderly patients
Pregnancy & Breastfeeding
Contraindicated in pregnancy and lactation; embryotoxic and teratogenic.
Key Drug Interactions
- CYP3A4 substrates
- QT prolonging agents
Contraindications
- Hypersensitivity to eribulin
- Pregnancy
- Lactation
Common side effects
- Neutropenia
- Peripheral neuropathy
- Nausea
- Fatigue
Counselling Points
- Avoid pregnancy during treatment
- Use contraception
- Monitor for signs of infection
Serious warnings
- Myelosuppression
- QT prolongation
- Severe neutropenia
Important Disclaimer
The Halaven 2ml Solution for injection professional information leaflet below is the property of Eisai Pharmaceuticals Africa and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
